Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion
This is a single arm, interventional pilot study of using chlorhexidine irrigation
intra-operatively and post-operatively among patients undergoing radical cystectomy with
urinary diversion. The intervention comprises of using irrigation of ileal conduit or
ileal neo...
Age: 18 years - 66+
Gender: All
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients
with BCG-unresponsive or exposed CIS NMIBC. Arm A will enroll 43 participants who have
cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will
enr...
Age: 18 years - 66+
Gender: All
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the future, as standard screening measure. Adult...
Age: 18 - 89 years
Gender: All
A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Researchers are looking for new ways to treat people with high-risk muscle-invasive
urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins
in cells that line the inside of the bladder and other parts of the urinary tract, such
as pa...
Age: 18 years - 66+
Gender: All
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT
followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the
treatment of participants with IR-NMIBC.
Age: 18 years - 66+
Gender: All
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435 by itself or when it is combined with other standard medicines
that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the
urinary sys...
Age: 18 years - 66+
Gender: All
Intravesical BCG vs GEMDOCE in NMIBC
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC)
patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a
non-inferior event-free survival (EFS) compared to standard treatment with intravesical
BCG. The pu...
Age: 18 years - 66+
Gender: All
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by
Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
It is necessary that ctDNA test results are linked to clinical outcomes in order to
demon...
Age: 18 years - 66+
Gender: All
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination
with intravenous (IV) cetrelimab and IV cetrelimab alone.
Age: 18 years - 66+
Gender: All
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative
enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node
dissection (PLND) compared with the current standard of care (neoadjuvant chemotherap...
Age: 18 years - 66+
Gender: All
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative
enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node
dissection (PLND) compared with the current standard of care (neoadjuvant chemotherap...
Age: 18 years - 66+
Gender: All
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study
of BT8009 given as a single agent and in combination with pembrolizumab in participants
with advanced solid tumors associated with Nectin-4 expression or in participants with
ad...
Age: 18 years - 66+
Gender: All
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial
of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with
metastatic urothelial cancer who have achieved at least stable disease on first-line...
Age: 18 years - 66+
Gender: All